Sanofi results: Genzyme doesn't paper over cracks, as emerging markets top US and EU
This article was originally published in Scrip
Sanofi reported 3% growth in sales in 2011, but with expiries of patents for major drugs still coming through, the company admitted that it a decline in profits would continue into 2012. This was despite the boost to sales provided by last year's acquisition of Genzyme.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.